Bristol Gets Five Primed For Immuno-Oncology Expansion
This article was originally published in The Pink Sheet Daily
Executive Summary
Bristol strengthens its leading role in the immuno-oncology space through a discovery and development collaboration with newly public biotech Five Prime, a deal that could be worth more than $350 million with earn-outs. The pharma also takes an equity stake in its new oncology partner.